Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000042872
JPRN-UMIN000042872Completed未知

Development and evaluation of Gaucher disease (GD) - specific patient reported outcome measurement (PROM) in Japan. - Development and evaluation of Gaucher disease (GD) - specific patient reported outcome measurement (PROM) in Japan.

Takeda Pharmaceutical Company Limited0 sites8 target enrollmentStarted: December 29, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
8
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Three main themes emerged from qualitative analysis of patient interviews: treatment status, patient burden, and social support systems. Commonly used words and the relationships between words identified through the hierarchical cluster and co-occurrence network analyses supported these themes and topics. These themes and topics were specific to patients with types 2 and 3 GD and will be used to inform the development of a HRQOL questionnaire specifically for patients with all GD types

Study Design

Study Type
Observational

Eligibility Criteria

Ages
ot applicable to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients: - Patients who have cognitive disabilities, - Patients who lack of fluency in Japanese. Caregivers: - Persons with cognitive disabilities - Persons with lack of fluency in Japanese

Investigators

Similar Trials

Completed
Not Applicable
Study to Evaluate Blood Cell Lines From Patients With Gaucher DiseaseGaucher Disease
NCT00351156Amicus Therapeutics50
Recruiting
Not Applicable
A Long-term Follow-up Study of Gaucher DiseaseGaucher Disease
NCT03190837Duke University200
Completed
Not Applicable
Assessment of Giant Cell Arteritis Medical Practices in FranceGiant Cell Arteritis
NCT03658889Chugai Pharma France306
Withdrawn
Not Applicable
A Screening Study Evaluating Disease Status of Gaucher Type I PatientsGaucher Disease, Type 1
NCT00795197Genzyme, a Sanofi Company
Completed
Phase 4
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction TherapyGaucher Disease
NCT04718779Takeda4